4DX (ASX) Research

Originally posted by Veecat: ↑

I cut my losses ($200k plus) and have found it prosperous making gains elsewhere since so do not regret this.

I think the real issue has been the over promise which another poster once said a said at a pre IPO meeting he went to the vibe was large US deals were imminent and if you look at the 08/10/2020 release this is when I got in based on the upbeat comments on pages 27 and 28 which did not materialise.

Slide 27 - being told clinical trials are complete when they weren't, or if they thought they were, they weren't.

Slide 28 - Terms like existing partnerships with some of the most prestigous hopsitals, KOL's have a strong understanding, platform already in use, 2 noted as paying revenue, significant revenue potential in the immediate term... 2 + years on and basicaliy no revenue from any of these 8 hospitals.

Granted this may have been their view and expectations but clearly 2 + years on we can see the expected revenue (or any real revenue) did not come to fruition and it would have contriburted to over inflating the share price and luring in investors like me and others here under an illusion. If they floated with none of these claims which turned out to be hot air it prob never trades above $1, plus Covid was going on to push it also.

I regret not selling out when after a few months nothing was announced and we were being told to do more clinical trials at these hospitals. I was questioning the company who had no answers and were more or less silent so also a warning sign. Same as when I questioned the 18/12/2020 release which said rollout would happen early in 2021 then each 4C went by with no revenue and no update even. See comments below, yet here we are with iMed only finally rolled out a year on and then the Sep 2022 qtr revenue blanks and we are told it is payment timing even though they have been scanning for 9 months? They never tell us numbers of scnas? Who could really trust this management if we are all being honest to ourselves?

'The scan was successfully completed in Victoria and marks the first commercial use of XV LVAS as the
Company begins to roll out its infrastructure nationally. Installation of XV LVAS is anticipated in hospitals
and imaging centres in Victoria as well as other states from early 2021.'

I do not buy the legal liability and crap about needing doctors to understand it, it is quite easy to look and see, my doubts would be doctors don't actually see it picking up fine tumors, it requires fluroscopy X-Ray I believe not regular X-Ray which is higehr radiation and another thing they don't make clear. I researched into how doctors read X-Rays and also did not see many cases where the 4DX would help. It may have applications for certain ongoing patients but how big is this market? It looks more beneficial to research areas. If it was going to be revolutionary in my view by now we would have seen the uptake of the technology.

I agree long term we may see them make it but as it stands to me management has minimal cfedibility, they have not delivered on their comments/promises, A CR may be needed soon given some of the cash they hold is set aside for the MRFF grant? Burning up $9 mill a quarter so by June 2023 be down to near $20 million and unlikely to be any real revenue based on iMed and how this is going.

Expand

Congrats on making so much money elsewhere... We all know your position on this... I just don't understand why you keep coming here to repeat it if you're not invested...Is this an "I told you so" moment?

You have been bearish and critical of the company for as long as I can remember and your expectations on how quickly things can be achieved in what is a highly bureaucratic and academic environment remain skewed in my humble opinion.

My thesis along with many others with realistic expectations around commercial timeframes stands... this is a top drawer stock with plenty of ongoing risk but also plenty of upside. You can jump out and TRADE the market if you wish... but picking when a company you believe had the potential to 10X or 50X or whatever is pure luck...

I'm holding my shares...

No.	Vol.	Price($)
6	82444	53.0¢

No.

Vol.

Price($)

82444

53.0¢

Price($)	Vol.	No.
54.5¢	35619	2

Price($)

Vol.

No.

54.5¢

35619

No.	Vol.	Price($)
6	82444	0.530
1	25000	0.525
1	5000	0.520
2	48776	0.515
2	20987	0.510

No.

Vol.

Price($)

82444

0.530

25000

0.525

5000

0.520

48776

0.515

20987

0.510

Price($)	Vol.	No.
0.545	35619	2
0.550	350546	3
0.555	9980	3
0.580	39104	1
0.600	13000	2

Price($)

Vol.

No.

0.545

35619

0.550

350546

0.555

9980

0.580

39104

0.600

13000

(20min delay)
Last 53.0¢		Change 0.000(0.00%)		Mkt cap ! $217.5M

Open	High	Low	Value	Volume
52.5¢	54.0¢	50.5¢	$433.4K	826.2K

Research, page-1128

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Research, page-1128

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News